6th Mar 2015 08:17
LONDON (Alliance News) - Shares in Tissue Regenix Group PLC are trading up 15% Friday morning after it said its DermaPure dermal allograft has received US health insurance coverage and reimbursement under Medicare.
Medicare is US national social insurance programme.
DermaPure is a skin substitute that works by taking donor skin and removing DNA and cells using the company's dCELL process to leave a natural scaffold that can be placed in the wound and aid natural healing.
DermaPure has received local coverage determination from the Medicare administrative contract that oversees jurisdiction J-H and jurisdiction J-L, covering Colorado, New Mexico, Oklahoma, Texas, Louisiana, Mississippi, Arkansas and Washington DC, Delaware, Maryland, New Jersey and Pennsylvania respectively.
This is the final step needed to allow an outpatient medical facility to be reimbursed for the product for qualified patients in these jurisdictions, Tissue Regenix said.
Shares in Tissue Regenix are trading up 15% at 22.40 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group